AddLife AB
STO:ALIF B
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
89.3353
168
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
AddLife AB
AddLife AB
Total Equity
AddLife AB
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AddLife AB
STO:ALIF B
|
Total Equity
kr5B
|
CAGR 3-Years
38%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
Total Equity
kr3.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Total Equity
kr3.8B
|
CAGR 3-Years
52%
|
CAGR 5-Years
34%
|
CAGR 10-Years
23%
|
|
|
G
|
Genovis AB
STO:GENO
|
Total Equity
kr207.6m
|
CAGR 3-Years
32%
|
CAGR 5-Years
48%
|
CAGR 10-Years
22%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Total Equity
kr1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
30%
|
CAGR 10-Years
17%
|
|
|
M
|
Magle Chemoswed Holding AB
STO:MAGLE
|
Total Equity
kr158.2m
|
CAGR 3-Years
11%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
AddLife AB
Glance View
AddLife AB engages in the ownership and acquisition of companies in niche segments under the healthcare sector. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2015-03-16. The firm markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The firm operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The firm operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
See Also
What is AddLife AB's Total Equity?
Total Equity
5B
SEK
Based on the financial report for Dec 31, 2023, AddLife AB's Total Equity amounts to 5B SEK.
What is AddLife AB's Total Equity growth rate?
Total Equity CAGR 5Y
40%
Over the last year, the Total Equity growth was 0%. The average annual Total Equity growth rates for AddLife AB have been 38% over the past three years , 40% over the past five years .
You don't have any saved screeners yet
